	US 12,258,420 B2
	Engineered IGA antibodies and methods of use
Jeanette Henrica Wilhelmina Leusen, Utrecht (NL); Johannes Gerardus Maria Evers, Utrecht (NL); and Geert Jan Van Tetering, Utrecht (NL)
Assigned to TigaTX, Inc., Boston, MA (US)
Filed by Tiga TX, Inc., Westerly, RI (US)
Filed on Jun. 9, 2021, as Appl. No. 17/343,249.
Application 17/343,249 is a continuation of application No. 17/091,897, filed on Nov. 6, 2020, granted, now 11,059,909.
Application 17/091,897 is a continuation of application No. PCT/NL2020/050217, filed on Mar. 27, 2020.
Claims priority of provisional application 62/824,864, filed on Mar. 27, 2019.
Prior Publication US 2021/0380720 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/42 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/4283 (2013.01) [C07K 16/283 (2013.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/41 (2013.01); C07K 2317/51 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/94 (2013.01)]

17 Claims

1. A pharmaceutical composition comprising an engineered immunoglobulin A subclass 2 (IgA2) antibody or a functional fragment thereof and a pharmaceutically acceptable carrier, diluent or excipient, wherein the engineered IgA2 antibody or a functional fragment thereof comprises an antibody antigen binding domain; and a constant domain, wherein the constant domain comprises an IgA2 heavy chain constant region, wherein the IgA2 heavy chain constant region comprises an IgA2 CH1 region, an IgA2 CH2 region, and an IgA2 CH3 region, wherein the IgA2 CH3 region comprises:

(a) an amino acid substitution at N135, and

(b) a deletion of C147 and Y148,

each relative to a wildtype (WT) IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.